Related Experiment Video
Updated: Aug 17, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
The management of cardiac disease in chronic uremia
1Division of Nephrology, Memorial University of Newfoundland, St. John's, Canada.
Insights
Cardiac disease is a major concern for patients with chronic uremia, presenting as cardiomyopathy with poor prognosis. Further research is needed to identify and test interventions for these conditions.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Chronic uremia significantly increases the burden of cardiac disease.
- Cardiomyopathy in uremia encompasses dilated cardiomyopathy, left ventricular hypertrophy, and ischemic heart disease.
- These cardiac conditions in uremic patients have a poor prognosis.
Purpose of the Study:
- To review the burden and risk factors of cardiac disease in chronic uremia.
- To identify potentially reversible risk factors for cardiac disease in dialysis patients.
- To highlight the need for randomized controlled trials (RCTs) for cardiac disease prevention and treatment in uremia.
Main Methods:
- Literature review of cardiac disease in chronic uremia.
- Identification of known risk factors associated with cardiac disorders.
- Discussion of potential interventions requiring further clinical trials.
Main Results:
- Key risk factors include uremia, anemia, hypertension, smoking, coronary artery disease, hyperparathyroidism, hyperlipoproteinemia, and left ventricular hypertrophy.
- Potentially reversible factors offer targets for intervention.
- The need for rigorous RCTs to validate interventions is emphasized.
Conclusions:
- Cardiac disease is a serious complication of chronic uremia, necessitating targeted interventions.
- Reversible risk factors provide opportunities for therapeutic strategies.
- Further research through RCTs is crucial to improve cardiac outcomes in dialysis patients.
Abstract:
The burden of cardiac disease is high in chronic uremia. Cardiomyopathy results from a combination of cardiac disorders, particularly dilated cardiomyopathy, left ventricular hypertrophy with normal systolic function, and ischemic heart disease. The prognosis for these cardiac disorders is poor. Known potentially reversible risk factors include uremia, anemia, hypertension, smoking, coronary artery disease, hyperparathyroidism, hyperlipoproteinemia, and left ventricular hypertrophy. Randomized controlled clinical trials of interventions that may prevent or ameliorate cardiac disease in dialysis patients are required. These interventions include normalization of hematocrit with erythropoietin compared with partial correction of anemia, increased amount of dialysis compared with that provided by a dialysis prescription of KT/V of 1., control of blood pressure using angiotensin-converting enzyme inhibitors compared with other antihypertensive agents, control of hyperlipidemia, and treatment of diabetes with agents that prevent collagen cross-linking.
Related Concept Videos
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

